Actualizar mis citas con la selección
Presentar
resultados
Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dillman NO, et al.
Tocilizumab for treatment of mechanically ventilated patients with COVID-19.
Clin Infect Dis 2020:11 de julio. [Ref.ID 103688]
Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JPT, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GDO, Gudnason V.
Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review.
PLOS Medicine 2008;5:78. [Ref.ID 82761]
Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T.
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trials.
Lancet 2008;371:998-1006. [Ref.ID 82453]
Smolen JS, Beauliez A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R, for the OPTION Investigators.
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
Lancet 2008;371:987-97. [Ref.ID 82452]
Pradhan A D, Manson JE, Rossouw J E, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger M B, Ridker P M.
Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease. Prospective analysis from the Women's Health Initiative Observational Study.
JAMA 2002;288:980-7. [Ref.ID 63099]
Actualizar mis citas con la selección